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Autism spectrum disorder (ASD) is a complex neurodevelopmental
disorder. Some anecdotal reports suggest that ASD is related to
exposure to ethyl mercury, in the form of the vaccine preservative,
thimerosal, and/or receiving the measles, mumps, rubella (MMR)
vaccine. Using infant rhesus macaques receiving thimerosal-
containing vaccines (TCVs) following the recommended pediatric
vaccine schedules from the 1990s and 2008, we examined behav-
ior, and neuropathology in three brain regions found to exhibit
neuropathology in postmortem ASD brains. No neuronal cellular
or protein changes in the cerebellum, hippocampus, or amygdala
were observed in animals following the 1990s or 2008 vaccine
schedules. Analysis of social behavior in juvenile animals indicated
that there were no significant differences in negative behaviors
between animals in the control and experimental groups. These data
indicate that administration of TCVs and/or the MMR vaccine to
rhesus macaques does not result in neuropathological abnormal-
ities, or aberrant behaviors, like those observed in ASD.
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Autism spectrum disorder (ASD) is a complex neurodevel-opmental disorder presenting in early childhood with a
current prevalence ranging from 0.7% to 2.64% in the United
States (1). ASD is defined by the presence of marked social deficits,
specific language abnormalities, and stereotyped repetitive patterns of
behavior (2). Genetic and environmental factors have been found to
play a role in the disorder (3, 4). The neuropathology of autism is
now beginning to be understood; however, there is still much to be
learned. Thus far, the major neuropathological changes observed in
autism are changes in neuronal size in the limbic system; decreased
numbers of Purkinje cells in the cerebellum; abnormalities in
the brainstem, neocortex, amygdala, and hippocampus; features
of cortical dysgenesis or migration disturbances; and alterations
in GABAergic and cholinergic systems [see Gadad et al. (3) and
Amaral (5) for reviews]. In many autism studies, comorbid
conditions such as seizure disorders or intellectual disabilities
contribute to the heterogeneity of the neuropathology.
An association between exposure to thimerosal-containing vac-
cines (TCVs) and developmental abnormalities has been debated
since 1999 when the US Food and Drug Administration determined
that children receiving multiple TCVs at a young age were at risk
for exceeding the Environmental Protection Agency’s safe ex-
posure limits for methylmercury (MeHg). Results from an In-
stitute of Medicine (IOM) review on the safety of childhood
vaccines found that there was not sufficient evidence to render
an opinion on the relationship between exposure to TCVs or the
measles, mumps, rubella (MMR) vaccine and developmental
disorders in children (IOM 2001) (6). The IOM review did,
however, note the possibility of such a relationship and recom-
mended further studies be conducted. A more recent second
review of TCVs and autism (IOM 2004) (7) came to the same
conclusion reached earlier: that there was no epidemiological data to
support a relationship between TCVs and childhood developmental
disorders. Several epidemiological studies sought to determine
whether TCVs resulted in neurodevelopmental disorders including
autism; however, both nonsignificant and significant associations have
been reported (8–12). Significant associations have been reported by
Thompson et al. (11), who investigated the association between
TCVs and immune globulins early in life and neuropsychological
outcomes in children at 7–10 y of age. The data included the eval-
uation of 1,047 children and their biological mothers and 24 neuro-
psychological tests. The only variable that was statistically significant
was tics; children who were exposed to higher doses of thimerosal
were more likely to exhibit tics. In a follow-up study by Barile et al.
(12) examining a subset of the data from Thompson et al. (11), they
found a significant association between thimerosal dosage and tics,
but only in boys. They found no statistically significant associations
between thimerosal exposure from vaccines early in life and six of the
seven neuropsychological constructs examined.
Concern regarding the safety of childhood vaccines has had a
major impact on immunization rates (13–16). It is of great im-
portance to determine whether TCVs play a significant role in
altering brain development and/or behaviors that mimic changes
observed in autism. The present study provides a comprehensive
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analysis of the influence of TCVs on the brain and behavior in a
nonhuman primate model. The study includes 79 rhesus ma-
caques in six groups (n = 12–16 per group): (i) Control, a control
group given saline injections; (ii) 1990s Pediatric, replicating the
pediatric vaccination schedule used for infants in the 1990s that
included several TCVs; (iii) 1990s Primate, replicating the pe-
diatric vaccination schedule used in the 1990s but accelerated
fourfold representing the faster development of infant macaques;
(iv) TCVs, only TCVs and no MMR; (v) MMR, only the MMR
vaccine; and (vi) 2008, the expanded pediatric schedule used in 2008
(and very similar to that used today, which also includes a prenatal
influenza vaccine; Table 1). For neuropathology, only animals in the
1990s and 2008 vaccine groups were studied because the 1990s
schedule had the highest thimerosal exposure, and the 2008 schedule
had the greatest number of different vaccines and is very similar to
the vaccine schedule currently recommended for US infants. Anal-
yses of early learning and cognition, from birth to 12 mo of age, in
the same animals used in this study was recently reported by Curtis
et al. (17).
Results
Social Behavior. Overall means and SDs for duration and fre-
quency of social and nonsocial behaviors scored for all animals
are shown in Table 2. A description of the specific behaviors
measured in this study is given in Table S1. The duration and
frequency of negative behaviors (e.g., Stereotypy, Rock-huddle-
self-clasp, Fear-disturbed, and Withdrawal) by animals in all
groups across the entire study period was very low. Behaviors
that had either a significant time main effect or a time × group
interaction are shown in Fig. 1 (Social: Positive Behaviors;
Nonsocial: Passive Behavior; and Nonsocial: Positive Behav-
ior). The Nonsocial Explore behavior was the most frequent of
the nine behaviors measured and presented the only instance of
a significant effect involving group: there was a significant time ×
group interaction [F(5, 393) = 4.17, P = 0.004]. Follow-up con-
trasts indicated that the Control animals exhibited significantly
more Nonsocial Explore behavior at the beginning of social liv-
ing compared with the 1990s Primate [t(393) = 3.61, P < 0.001],
the 1990s Pediatric [t(393) = −7.46, P < . 001], the MMR [t(393)
= −2.72, P = 0.011], and the TCV [t(393) = −2.48, P = 0.017] groups
(Fig. 1). However, there were no significant differences in any
behavior measured between the control and experimental groups
after 6 mo of social living (at ∼18 mo of age).
Brain. The neuroanatomical analyses were first performed in
brains from the 1990s Primate and 2008 groups, as animals in
these groups received the highest amount of EtHg exposure
(1990s Primate) or the most extensive vaccine exposure (2008).
Because no neuronal differences were found in either of these
vaccine groups compared with the control group, no additional
vaccine groups were fully studied.
Cerebellum. Abnormalities in the cerebellum have been reported
in postmortem ASD brains (18, 19). Both histological and neu-
rochemical analyses were performed on the cerebellar tissues in
the present study.
Cerebellar volume and Purkinje cell number. Stereological methods
were used to estimate the total number of Purkinje cells (Fig. 2) in
one hemisphere. There were an average of ∼800,000 cells in one
hemisphere, with a density of 270 cell/mm3 and an overall volume of
∼3,000 mm3. No difference in cell number, density, or cerebellar
hemisphere volume was observed in the 1990s Primate and 2008
groups compared with the Control group. We also examined
Purkinje cell number in some of the animals in the TCV and
MMR groups, and they were similar to that of the Control group
(Table S2).
Purkinje cell size. Cell size (area) was measured in both Nissl-
stained sections and in calbindin-immunostained sections. The
calbindin-containing Purkinje cells were markedly larger than
the calbindin-negative/Nissl-positive cells [Control mean ± SD
(μm2) = 488.5 ± 7.9 and 273.1 ± 7.7; n = 8], but there was no
difference in cell size between the Control and the 1990s Primate
group for either calbindin-positive cells or Nissl-positive cells,
respectively (Table S3).
Cerebellar proteins. Western blots were run to measure the levels
of Purkinje cell-related proteins—calbindin and GAD-67—and
glial proteins—Iba1 (microglial marker) and GFAP (astrocyte
marker) (Fig. 3). There were no differences in the protein levels in
the 1990s Primate or 2008 groups compared with the Control group
(n = 8/group). Because different regions of the cerebellum were
used for the protein assays, it was important to ensure that the
results reflect “whole cerebellum differences.” Therefore, we
measured levels of the four proteins in five different cerebellar
regions and found that all of the regions had similar levels of these
proteins (Fig. S1).
Table 1. Vaccination schedules used for the six groups of
animals
Group N Vaccines administered
Control 16 None, all saline placebos
1990s Pediatric 12 Vaccine regimen as recommended in
the 1990s
1990s Primate 12 Vaccine regimen as recommended
in the 1990s accelerated fourfold
TCV’s 12 All TCVs and saline placebo for MMR
MMR 15 MMR only, all others replaced with
saline placebo
2008 12 Vaccine regimen recommended in 2008
Table 2. Duration and frequency (mean ± SD) of social and nonsocial behaviors scored for all
79 animals
Behavior
Social Nonsocial
Duration (SD)* Frequency (SD) Duration (SD)* Frequency (SD)
Passive 7.77 (6.95) 0.46 (0.25) 1.67 (2.85) 0.02 (0.03)
Explore 3.51 (3.30) 0.45 (0.19) 164.89 (15.18) 17.29 (2.74)
Play 14.95 (5.37) 3.67 (1.16) 4.01 (2.02) 2.56 (0.97)
Sex 0.95 (1.00) 0.16 (0.14) 0.00 (0.00) 0.00 (0.00)
Aggression 0.03 (0.07) 0.01 (0.02) 0.02 (0.12) 0.00 (0.01)
Withdrawal 0.04 (0.14) 0.01 (0.03) 0.00 (0.00) 0.00 (0.00)
Fear-disturbed 0.29 (0.53) 0.06 (0.09) 0.34 (0.72) 0.06 (0.11)
Rock-huddle-self-clasp 0.02 (0.15) 0.00 (0.01) 0.00 (0.00) 0.00 (0.00)
Stereotypy 0.00 (0.00) 0.00 (0.00) 0.27 (0.72) 0.03 (0.07)
Scoring was collected during 5-min focal periods collected 5 d/wk from ∼12 to 18 mo of age. Additional
behaviors scored but not included in the analyses included eating, drinking, scratching, and self-grooming.
*Duration reported in seconds. Frequency reported as number of events per session.
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Hippocampus. The CA1 neurons in the hippocampus have been
reported to be reduced in size in postmortem brains from chil-
dren with autism (18).
CA1 cell size. Cell size (area) was measured in Nissl-stained
sections at a rostral (section 100), middle (section 200), and a
caudal (section 300) level of the CA1 region (Fig. 4). Approxi-
mately 250–450 cells were measured per animal, each with a
clear nucleolus at the three levels of the nucleus. There was no
significant reduction in cell area for the 1990s Primate group vs.
Control group or for the 2008 group vs. Control group.
Neurogenesis. We sought to determine whether the birth of
new dentate granule neurons was altered by the 1990s Primate
vaccination schedule. Using doublecortin immunostaining, we
counted the number of these neurons in five rostral-caudal
sections/brain in the Controls and animals from the 1990s
Primate group. There was no difference in the total number of
cells per brain between the two groups (mean ± SEM for
control brains: 4,180 ± 308 neurons, and 3,983 ± 368 neurons in
the 1990s Primate group; n = 5/group; Fig. S2).
Dentate gyrus area.We examined the area of the granule cell layer
of the dentate gyrus in the Control, 1990s Primate, and 2008
groups at eight rostral-caudal levels through the structure (Fig. 5).
A two-way ANOVA was run to compare area of the dentate gyrus
in these three groups across the rostral-caudal extent of the nu-
cleus. There was no significant difference in area among the three
groups (P = 0.7565); however, as expected, there was a significant
effect for rostral-caudal level (P < 0.0001).
Amygdala. Abnormalities have been reported for the amygdala in
ASD subjects (20). We measured the volume of the entire amygdala
and of the lateral nucleus of the amygdala and the cell size and cell
number for the lateral nucleus (Fig. 6). The volume of the amygdala
was not significantly different in animals receiving either the 1990s
Primate (n = 12) or 2008 (n = 8) vaccination schedules compared
with the Controls (n = 16). In these same animals, we measured the
volume and number of neurons in the lateral nucleus of the
amygdala, and there was no difference among the three groups.
Finally, the cell size in the lateral nucleus was not changed by either
the 1990s Primate or 2008 vaccination schedules.
Discussion
The association between exposure to TCVs and developmental
outcomes has been debated since 1999 when the US Food and Drug
Administration determined that children who received multiple
TCVs at a young age were at risk for exceeding the Environmental
Protection Agency’s safe exposure limits for MeHg. However, the
safety limits for EtHg, found in TCVs, has not been extensively
tested for its relationship with childhood developmental disorders.
In postmortem brains of subjects with ASD, reductions in the
number of cerebellar Purkinje cells (18, 19) and amygdala lateral
nucleus cells (20), and reductions in the cell size of CA1 hippo-
campal cell (18) have been reported. In the present study, infant
male rhesus macaques received TCVs following the pediatric
schedule from the 1990s (e.g., hepatitis B vaccine, diphtheria, tet-
anus, acellular pertussis vaccine, Haemophilus influenza B vaccine,
measles, mumps, rubella vaccine) and the expanded 2008 schedule,
and were euthanized at ∼18 mo of age. We examined cerebellar,
amygdalar, and hippocampus neurons (n = 8–16/group), as these
brain regions have been reported to be abnormal in postmortem
brains from subjects with autism. There were no significant dif-
ferences in Purkinje cell number or cell size, cerebellar volume,
CA1 cell size, dentate gyrus volume, hippocampal neurogenesis, or
lateral nucleus of the amygdala volume/cell number in animals in
the 1990s Primate or 2008 groups compared with control animals.
Fig. 1. Analysis of behavioral data. Fitted values from analytical models of
social and nonsocial behavior for groups from age 12 to 18 mo, back-
transformed with antilog. Durations of positive behaviors (play, sex, and
aggression) were summed for each animal. Only behaviors that showed ei-
ther a significant time main effect or a time × group interaction are shown:
(A) Social: Positive Behavior, (B) Nonsocial: Explore Behavior, (C) Nonsocial:
Passive Behavior, and (D) Nonsocial: Positive Behavior. Nonsocial: Explore
Behavior demonstrated the only significant time × group effect, and this was
only significant at the beginning of social living. Duration of behaviors is
shown in seconds.
Fig. 2. Cerebellar Purkinje cells. Purkinje cells are illustrated in sections
stained with Cresyl violet (A and B) and calbindin-D28k/neutral red (C–E).
C illustrates two regions, shown at higher power in D and E, illustrating that
not all Purkinje cells stain positive for calbindin (D vs. E). There was no dif-
ference in the Purkinje cell number, cell density, or cerebellar hemisphere
volume among the Control, 1990s Primate and 2008 groups (F–H). Sample
size: n = 16 for Control; n = 12 for 1990s Primate; n = 8 for 2008. [Scale bars,
(A) 50 μm; (B) 10 μm; (C) 2.2 mm; (D) 200 μm; and (E) 200 μm.]
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Our data do not support a role for TCVs in the neuropathology of
ASD. A similar study examining the effects of TCVs on mouse
neuropathology also reported normal hippocampal architecture
with no changes in volume or numbers of neurons in the CA1
region or dentate gyrus (21).
There are limited studies on whether low-dose thimerosal via
vaccination causes behavioral symptoms that resemble autism.
Barile et al. (12) investigated the association between the receipt
of TCVs and immune globulins early in life and neuro-
psychological outcomes in children at 7–10 y of age. The data
were originally created by evaluating >1,000 children and
their biological mothers. They found no statistically significant
associations between thimerosal exposure from vaccines early in
life on six of the seven variables, but there was a small but sta-
tistically significant association between early thimerosal expo-
sure and the presence of tics in boys.
There is emerging evidence that autism may result from a ma-
ternal immune activation (MIA) during pregnancy. Several animal
studies have examined the potential for prenatal viral exposure to
induce aberrant behavioral outcomes in the offspring (22), and
there are clinical reports of a maternal cytokine response to viral
pathogens, suggesting a possible mechanism in the precipitation of
these aberrant behaviors (23, 24). Maternal exposure to influenza
and other viruses during pregnancy has been implicated in autism
[reviewed by Zerbo et al. (25)]. In this study, pregnant dams whose
infants were assigned to the 2008 group received a single influenza
vaccine, containing thimerosal, to mimic vaccine recommendations
for pregnant women. No evidence of either behavioral or neuro-
anatomical changes were observed in infants receiving a prenatal
influenza vaccine, nor did our previous study identify any effects of
prenatal influenza exposure on measures of early learning and
cognition (17), suggesting that exposure to a single prenatal in-
fluenza TCV does not result in MIA.
In the present study, we examined social behavior in six groups
of animals. Behaviors reported here were scored in animals from
∼13 to 18 mo of age. During this time, animals spent very little
time engaged in negative behaviors such as Stereotypy, Rock-
huddle-self-clasp, Fear-disturbed, and Withdrawal. In fact, there
were virtually no instances of any stereotypy, a behavior char-
acteristic of children with autism. Similar data were obtained
in this same cohort of animals when examining behavior from
∼30 d to 12 mo of age (17). Overall, animals developed the
normal repertoire of behaviors that is typical of animals of this
age (26). Several primate studies have examined the effects of
neurotoxicants on social behavior. Oral MeHg given prenatally
alters the expression of social behavior in primates such that
exposed offspring spend more time being passive and less time
engaged in play behaviors with peers (26). Similarly, studies of
postnatal lead exposure (27, 28) or prenatal TCDD exposure
(29) have also produced a negative impact on social behavior in
macaques. In contrast, exposure to low-dose TCVs via vaccina-
tion in our study did not significantly impact behavior.
There are several limitations to the present study. The 1990s
Primate group was given an accelerated schedule of vaccina-
tions due to the faster development of the visual system, pattern
recognition, and object permanence in infant macaques (30, 31). It
was therefore necessary to determine the appropriate timing for
administering vaccines. In primates, there is a theoretical de-
velopmental ratio of 4:1, such that 4 wk of human development is
comparable to 1 wk for a primate (32). Low-dose thimerosal ex-
posure studies in primates have therefore used an accelerated
schedule of exposure based on this developmental ratio (33, 34). It
is possible that receiving multiple TCVs in an accelerated time
frame could induce neurotoxicity in infant macaques, but this was
not evident in tests of early learning and cognition (17). Likewise, in
the present study, we did not find neuropathological or behavioral
abnormalities in animals receiving TCVs. Neurobehavioral assess-
ments followed very detailed protocols that have been used at the
primate facility for more than three decades (35, 36). There were
three testers involved in the scoring of social behavior data and each
passed periodic reliability training to high standards. Therefore,
although it is possible that primate behavioral scoring drifted over
the course of this study (5 y), this should not have affected the group
comparisons. Stereological analyses can result in biased data if
suitable controls are not included. In the present study all cell
number and cell size measurements were made with the person
doing the measurements blind as to the experimental condition of
the animal. In addition, at least two different people made the
measurements to be certain of the validity of the data. Sometimes
the neuroanatomical boundaries of nuclei are difficult to reliably
define in all brain sections. To be certain of the neuroanatomical
boundaries of the hippocampus CA1, the amygdala, and the lateral
nucleus of the amygdala, we relied on the macaque primate brain
atlas of Paxinos et al. (37), which allowed for a clear demarcation of
the three brain regions. The present study focused on three brain
regions found to be abnormal in postmortem ASD brains (cere-
bellum, amygdala, and hippocampus); however, the cerebral cortex
has also been implicated in ASD neuropathology (38, 39). The
cerebral cortex was not analyzed because there were no behavioral
abnormalities observed in the present study nor was there neuro-
pathology in the three regions examined.
In summary, analyses of postmortem brains from ASD sub-
jects have often found decreases in Purkinje cell number (19)
and cell size. We found no changes in Purkinje cell density or
cell size in treated primates, and there was no difference in
cerebellar calbindin, GAD-67, GFAP, or CD11b protein levels
in the 1990s Primate or 2008 groups. Amygdala deficits have
also been previously reported in autism. For instance, Schumann
and Amaral (20) reported a 14% decrease in amygdala lateral
Fig. 3. Western blots of cerebellar proteins. (A) No differences were found
in protein amounts for control, 1990s Primate, and 2008 groups. (B) Quan-
tification of optical density values. Sample size: n = 8 for each of the three
groups.
Fig. 4. CA1 cells in the hippocampus. (A) Location of the CA1 region.
(B) Neurons at a higher magnification. Red arrows point to cells with a
visible nucleolus. (Inset, Right) High magnification view of two neurons,
one with a visible nucleolus. (C) Cell size data for Control (n = 16), 1990s Primate
(n = 12), and 2008 (n = 8) groups. [Scale bars, (A) 1 mm and (B) 25 μm.]
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nucleus cell number in postmortem ASD brains. We did not ob-
serve any changes in amygdala volume, lateral nucleus cell num-
ber, or cell volume in the 1990s Primate group. Postmortem
studies (18) report smaller CA1 neurons in ASD cases, but in the
present study we did not identify changes in CA1 cell size following
administration of TCVs. Behaviors scored from ∼13 to 18 mo
of age revealed that animals spent very little time engaged in
autism-related behaviors. For instance, there were virtually no
instances of stereotypy, a behavior characteristic of children with
autism and that can be generated by administration of various
CNS toxicants during this developmental period. Overall, animals
in each group developed the normal repertoire of behaviors that is
typical of animals of this age. Our data strongly support the con-
clusion that childhood TCVs do not produce ASD-like neuro-
pathology or behavioral changes in the nonhuman primate.
Methods
Study Design. Animal procedures followed the guidelines of the Animal
Welfare Act and the Guide for Care and Use of Laboratory Animals of the
National Research Council (40). All experimental protocols were approved by
the University of Washington Institutional Animal Care and Use Committee.
A total of 79 male infant macaques were studied in six groups: (i) Control
(n = 16), animals received saline injections in place of vaccines; (ii) 1990s
Pediatric (n = 12), animals received vaccines following the pediatric schedule
recommended in the 1990s; (iii) 1990s Primate (n = 12), animals received
vaccines recommended in the 1990s but on an accelerated schedule; (iv) TCV
(n = 12), animals received all TCVs but no MMR vaccines following the
accelerated schedule; (v) MMR (n = 15), animals only received the MMR
vaccine but no TCVs following the accelerated schedule; and (vi) 2008 (n =
12), animals received vaccines recommended in 2008 but on an accelerated
schedule. Infants were assigned to a peer group of four animals, with
multiple study groups being tested each year when possible (17).
Animal Husbandry and Rearing Protocols. All infants were nursery-raised
following standardized protocols (41, 42). Details are provided in SI Methods.
Vaccine Dosing and Administration. The vaccines used in this study are shown in
Table S4. To recreate the required TCVs, thimerosal was added to the vaccines as
described previously (17). Details are provided in SI Methods and Tables S5 and S6.
Assessments of Behavior. Social behavior was evaluated daily within the home
cage for each peer group from ∼12 to 18 mo of age. Each home cage contained
wire mesh shelves, climbing platforms, and toys. Scoring was conducted by a
blinded social tester in 5-min focal periods using a coding system of mutually
exclusive and exhaustive behaviors (26). All testers were trained for 3–4 mo
using the following protocol. Trainee testers score behaviors for the 5-min focal
sessions along with a trained tester. This training is done for 10–15 sessions each
with young infants, older infants, and young juveniles. Testers must attain a
κ reliability score of 0.60 or better with their trainer with each age group
being tested. All testers are retested with this procedure for reliability at 6-mo
intervals. In the event of any code disagreements at or below chance levels
(which was a rare occurrence), testers are retrained on the meaning of that
code or codes. The three testers on this project had been social testing for 5–15 y,
achieving the κ retest reliability standard at a typical value of 0.80 or better.
Additional details are provided in SI Methods.
Preparation of Brain Tissues. Brains underwent a hemidissection with alter-
nate hemispheres processed for immersion fixation in paraformaldehyde/PBS
(pH 7.4). Tissues were postfixed in the same fixative for several weeks. After
cryoprotection in 20% (wt/vol) sucrose/formalin/PBS (pH 7.4) for 2–3 d at 4 °C,
the forebrain was blocked in the coronal plane, frozen, and cut at 60-μm
thickness on a sliding microtome.
See SI Methods for details on the preparation of brain tissues, immuno-
histochemistry, and immunoblot analysis.
Stereological Analysis. All measurements were made using a Leica DMRE mi-
croscope attached to a Q-Imaging camera with Stereo-investigator software
version 9.1,whichwas connected to aDell Precision 450workstationusing Stereo
Investigator software (MicroBrightField).
Cell counting. For counting Nissl-positive Purkinje neurons in the cerebellum,
10 sections were examined that were spaced 1.2 mm apart from medial to
lateral through an entire cerebellar hemisphere. For counting neurons in the
lateral nucleus of the amygdala, seven sections were examined that were
spaced 0.6 mm apart across the entire rostral-caudal dimension.
Soma size. For measuring cell size (area), two sagittal sections (sections 100 and
300) were examined in the cerebellum, and three rostral-caudal sections were
examined in the CA1 region of the hippocampus (sections 100, 200, and 300).
Volume. For volumemeasurements of the cerebellum, amygdala, lateral nucleus
of the amygdala, and dentategyrus of thehippocampus, 10, 7, 9, and 8 sections,
respectively, that were spaced 0.6 mm apart were measured (i.e., every 10th
section). Further details are provided in SI Methods and Tables S5 and S6.
Statistical Analysis. ANOVA was used to compare cell sizes and areas, and
nuclear volumes, and multilevel modeling for analysis of behaviors among
the animal groups. P < 0.05 was considered statistically significant.
Fig. 5. The dentate gyrus. The size and shape of the dentate gyrus changes
from rostral (A) to caudal (C). Illustrations were taken from sections 191, 251,
and 331 (A–C). (D) Area of the dentate gyrus in the three groups of animals
(Control, n = 12; 1990s Primate, n = 12; and 2008, n = 8). No group difference
was found (ANOVA, P = 0.7565). [Scale bars, (A–C) 650 μm.]
Fig. 6. The amygdala was studied in three groups of animals: Control, 1990s
Primate, and 2008. (A–F) Sections through the rostral-caudal extent of the
amygdala stained for Nissl substance. Outlines are provided for the amygdala
borders, and the lateral nucleus of the amygdala (L). The amygdala volume (G),
lateral nucleus of the amygdala volume (H), lateral nucleus of the amygdala cell
area (I), and lateral nucleus of the amygdala cell number (J) did not change in
the 1990s Primate, 2008, and Control groups. Sample size: n = 12 for Control;
n = 12 for 1990s Primate; n = 8 for 2008. (Scale bar, 2 mm).
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